Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
50
Recruiting, any sponsor type, condition "IgA nephropathy"
By trial status
The same filters, counted in each status. Pick one to switch.
50 trials
Showing 1 to 25, recently updated first.
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07850752 · 340 participants (planned) · Start Nov 11, 2026 · Primary completion Sep 17, 2028
Drug: zigakibart; atrasentan and 1 more · For: IgA Nephropathy (IgAN)
Sites: Huntsville, Alabama; Fremont, California; Newark, Delaware · 11 sites in all
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringePivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07890909 · 40 participants (planned) · Start Nov 13, 2026 · Primary completion Dec 12, 2027
Drug: Povetacicept; Sibeprenlimab · For: Immunoglobulin A Nephropathy
Sites: Orlando, Florida; Lawrenceville, Georgia
ADARx Pharmaceuticals, Inc.Industry
NCT06989359 · 85 participants (planned) · Start Aug 28, 2025 · Primary completion Apr 30, 2030
Drug: ADX-038 Dose Level 2; ADX-038 Dose Level 1 and 1 more · For: IgAN; C3G; Complement-mediated Kidney Disease and 2 more
Sites: Doral, Florida; Miami, Florida; Pembroke Pines, Florida · 38 sites in all
- Study of Ravulizumab in Pediatric Participants With Primary IgANPivotal-lookingRecruiting
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT07024563 · 36 participants (planned) · Start Jun 14, 2025 · Primary completion Nov 29, 2028
Drug: Ravulizumab · For: IgAN; IgAVN; Immunoglobulin A Nephropathy and 3 more
Sites: Palo Alto, California; Aurora, Colorado; London, Canada · 19 sites in all
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07498335 · 28 participants (planned) · Start Aug 6, 2026 · Primary completion Sep 15, 2031
Drug: Drug: Atrasentan · For: Berger Disease; Bergers Disease; IgA Nephropathy and 3 more
Sites: Neptune City, New Jersey; Cincinnati, Ohio; Oklahoma City, Oklahoma · 23 sites in all
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06963827 · 347 participants (planned) · Start Jul 15, 2025 · Primary completion Sep 7, 2028
Drug: Mezagitamab; Placebo · For: Kidney Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Surprise, Arizona · 186 sites in all
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyPivotal-lookingRecruiting
Jade Biosciences, Inc.Industry
NCT07902817 · 480 participants (planned) · Start Dec 2026 · Primary completion Jun 2029
Drug: JADE101; Placebo · For: IgA Nephropathy (IgAN)
Sites: Arvada, Colorado; Lauderdale Lakes, Florida; Atlanta, Georgia · 4 sites in all
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat GlomerulonephritisRecruiting
Kira Pharmacenticals (US), LLC.Industry
NCT05517980 · 52 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 2028
Drug: KP104 · For: Glomerulonephritis
Sites: Beijing, China
Jade Biosciences, Inc.Industry
NCT07541287 · 30 participants (planned) · Start May 19, 2026 · Primary completion Jan 2029
Drug: JADE101 · For: IgA Nephropathy
Sites: Chula Vista, California; Arvada, Colorado; Denver, Colorado · 22 sites in all
- A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07773727 · 120 participants (planned) · Start Nov 5, 2026 · Primary completion Oct 29, 2029
Drug: ARGX-121; Placebo · For: Immunoglobulin A Nephropathy (IgAN)
Sites: Valencia, California; Miami, Florida; Pembroke Pines, Florida · 11 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07146906 · 32 participants (planned) · Start Mar 26, 2026 · Primary completion Jul 12, 2030
Drug: zigakibart · For: Immunoglobulin A Nephropathy (IgAN)
Sites: San Francisco, California; Denver, Colorado; Acworth, Georgia · 30 sites in all
- A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)Pivotal-lookingRecruiting
BiogenBiogen (BIIB)
NCT06935357 · 454 participants (planned) · Start May 8, 2025 · Primary completion May 31, 2027
Drug: Felzartamab; Placebo · For: Immunoglobulin A Nephropathy (IgAN)
Sites: Little Rock, Arkansas; Apple Valley, California; Carlsbad, California · 265 sites in all
- Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN StudyPivotal-lookingRecruiting
Centre Hospitalier Universitaire de Saint EtienneAcademic, hospital or other
NCT06350630 · 334 participants (planned) · Start Jun 26, 2025 · Primary completion Dec 31, 2027
Drug: Hydroxychloroquine Oral Tablet; Placebo oral tablet · For: IgA Nephropathy
Sites: Clermont-Ferrand, France; Lyon, France; Marseille, France · 8 sites in all
Mayo ClinicAcademic, hospital or other
NCT06676579 · 16 participants (planned) · Start Jun 9, 2025 · Primary completion Mar 2028
Drug: Avacopan; Prednisone and 2 more · For: IgA Nephropathy (IgAN)
Sites: Jacksonville, Florida; Rochester, Minnesota
- A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04557462 · 540 participants (planned) · Start Sep 20, 2021 · Primary completion Dec 4, 2030
Drug: LNP023 · For: Primary IgA Nephropathy
Sites: Glendale, Arizona; San Diego, California; San Dimas, California · 161 sites in all
Akebia TherapeuticsIndustry
NCT06419205 · 30 participants (planned) · Start Jul 30, 2026 · Primary completion Feb 2028
Drug: ADX-097 · For: IgA Nephropathy; Lupus Nephritis (LN); C3 (Complement Component 3) Glomerulopathy
Sites: Hollywood, Florida; Lawrenceville, Georgia; Orangeburg, South Carolina · 4 sites in all
Sitala Bio LTDIndustry
NCT07606352 · 15 participants (planned) · Start Aug 4, 2026 · Primary completion Jul 2027
Drug: STL303; STL303 and 1 more · For: IgAN
Sites: Newcastle, Australia; Penrith, Australia; Sydney, Australia · 8 sites in all
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06994845 · 31 participants (planned) · Start Nov 27, 2025 · Primary completion Jun 28, 2030
Drug: iptacopan · For: Primary Immunoglobulin A Nephropathy (IgAN)
Sites: Madera, California; Aurora, Colorado; Gainesville, Florida · 20 sites in all
- Chinese Adults With Kidney DiseaseRecruiting
ADARx Pharmaceuticals, Inc.Industry
NCT07522099 · 30 participants (planned) · Start May 21, 2026 · Primary completion Jul 10, 2028
Drug: ADX-038; Telitacicept · For: Immunoglobulin A Nephropathy (IgAN); Complement 3 Glomerulopathy (C3G); IC-MPGN
Sites: Shenzhen, China; Guiyang, China; Zhengzhou, China · 9 sites in all
- Efficacy and Safety of Nefecon on Prevention of Relapse of IgA NephropathyPivotal-lookingRecruiting
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT07604311 · 288 participants (planned) · Start Jun 23, 2026 · Primary completion Dec 1, 2028
Drug: NEFECON; Placebo · For: IgA Nephropathy (IgAN)
Sites: Guangzhou, China
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06858319 · 220 participants (planned) · Start Jul 28, 2025 · Primary completion Jun 25, 2031
Drug: zigakibart · For: Kidney Diseases; Kidney Diseases, Chronic; Urological Diseases and 5 more
Sites: Denver, Colorado; Orlando, Florida; Iowa City, Iowa · 26 sites in all
Everest Medicines (China) Co.,Ltd.Industry
NCT07614477 · 45 participants (planned) · Start May 20, 2026 · Primary completion Dec 31, 2028
Drug: EVER001 · For: Minimal Change Disease (MCD); IgA Nephropathy (IgAN); Focal Segmental Glomerulosclerosis (FSGS)
Sites: Beijing, China; Tianjin, China
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.Recruiting
Nanjing Bioheng Biotech Co., Ltd.Industry
NCT07203404 · 96 participants (planned) · Start Jul 24, 2025 · Primary completion Jul 23, 2027
Drug: RD06-05 CART Cell Injection · For: SLE; LN; ANCA Associated Vasculitis and 6 more
Sites: Shanghai, China
Walden BiosciencesIndustry
NCT06466135 · 96 participants (planned) · Start Jul 2, 2024 · Primary completion Mar 2027
Drug: WAL0921; Placebo · For: Diabetic Nephropathies; Primary Focal Segmental Glomerulosclerosis; Minimal Change Disease and 2 more
Sites: Los Angeles, California; Denver, Colorado; Tamarac, Florida · 50 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06797518 · 20 participants (planned) · Start Feb 21, 2025 · Primary completion Nov 27, 2027
Drug: Iptacopan · For: Glomerulonephritis, IGA; Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Los Angeles, California; Orlando, Florida · 19 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.